Currently, some therapeutic interventions by targeting aberrantly expressed co-stimulatory/co-inhibitory genes have been studied as promising therapeutic methods for autoimmune diseases, such anti-CD40L drugs and CTLA-4Ig (86–89). Here, CD40LG is linked to autoimmune disease.